Laurus Labs (LAURUSLABS.NS) Stock Price

Laurus Labs Price

NSE·CLOSED
1,816.20INR+23.50 (+1.30 %)
Market closed

Revenue has compounded at 15.3% per year over the past 11 years to 55.54 B INR. Earnings per share have grown at 12.4% per year over the last 11 years. Laurus Labs's net margin stands at 6.5%, down from 20.4% several years earlier. Laurus Labs currently offers a dividend yield of about 0.09%. The payout ratio is around 24% of earnings. The dividend has grown at 0.8% per year over the past 8 years. Analysts set a median price target of 1,060.80 INR, implying 41.6% below the current price. Of 20 analysts, 5 rate the stock a buy — an overall Sell consensus. The stock trades about 121% above its 52-week low.

Laurus Labs stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Laurus Labs over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Laurus Labs stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Laurus Labs's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Laurus Labs Stock Price History
DateLaurus Labs Price
7/31/20261,816.20 INR
7/30/20261,792.70 INR
7/29/20261,781.30 INR
7/28/20261,735.20 INR
7/27/20261,713.40 INR
7/24/20261,601.20 INR
7/23/20261,574.70 INR
7/22/20261,577.80 INR
7/21/20261,593.20 INR
7/20/20261,558.90 INR
7/17/20261,537.60 INR
7/15/20261,554.30 INR
7/14/20261,560.70 INR
7/13/20261,558.60 INR
7/10/20261,537.80 INR
7/9/20261,507.40 INR
7/8/20261,469.20 INR
7/7/20261,477.40 INR
7/6/20261,529.20 INR
7/3/20261,542.10 INR
7/2/20261,528.00 INR
7/1/20261,493.30 INR
6/30/20261,517.40 INR
6/29/20261,500.30 INR
6/25/20261,450.00 INR
6/24/20261,454.20 INR
6/23/20261,481.00 INR
6/22/20261,435.90 INR
6/19/20261,412.90 INR
6/18/20261,368.80 INR
6/17/20261,369.80 INR
6/16/20261,376.40 INR
6/15/20261,393.30 INR
6/12/20261,394.30 INR
6/11/20261,390.80 INR
6/10/20261,409.70 INR
6/9/20261,424.40 INR
6/8/20261,404.70 INR
6/5/20261,446.80 INR
6/4/20261,427.20 INR
6/3/20261,394.30 INR
6/2/20261,382.60 INR
6/1/20261,388.40 INR
5/29/20261,362.00 INR
5/27/20261,381.70 INR
5/26/20261,373.90 INR
5/25/20261,356.30 INR
5/22/20261,343.50 INR
5/21/20261,351.00 INR
5/20/20261,354.50 INR
5/19/20261,344.90 INR
5/18/20261,327.30 INR
5/15/20261,323.60 INR
5/14/20261,315.50 INR
5/13/20261,280.50 INR
5/12/20261,268.00 INR
5/11/20261,266.80 INR
5/8/20261,228.30 INR
5/7/20261,206.50 INR
5/6/20261,177.60 INR
5/5/20261,164.10 INR
5/4/20261,166.40 INR
5/1/20261,100.95 INR
4/30/20261,100.95 INR
4/29/20261,106.10 INR
4/28/20261,090.45 INR
4/27/20261,123.55 INR
4/24/20261,113.45 INR
4/23/20261,129.00 INR
4/22/20261,096.10 INR
4/21/20261,114.35 INR
4/20/20261,129.50 INR
4/17/20261,135.75 INR
4/16/20261,128.35 INR
4/15/20261,117.60 INR
4/13/20261,087.80 INR
4/10/20261,098.35 INR
4/9/20261,083.70 INR
4/8/20261,082.45 INR
4/7/20261,057.45 INR
4/6/20261,058.20 INR
4/2/20261,042.90 INR
4/1/20261,038.80 INR
3/30/2026992.70 INR
3/27/20261,008.80 INR
3/25/20261,023.50 INR
3/24/2026992.60 INR
3/23/2026961.40 INR
3/20/2026987.20 INR
3/19/2026944.90 INR
3/18/2026983.40 INR
3/17/2026968.70 INR
3/16/2026960.80 INR
3/13/20261,003.40 INR
3/12/20261,046.80 INR
3/11/20261,041.00 INR
3/10/20261,038.00 INR
3/9/20261,021.00 INR
3/6/20261,026.20 INR
3/5/20261,045.90 INR
3/4/20261,030.60 INR
3/2/20261,065.00 INR
2/27/20261,075.80 INR
2/26/20261,092.75 INR
2/25/20261,076.35 INR
2/24/20261,028.50 INR
2/23/20261,017.05 INR
2/20/20261,019.00 INR
2/19/20261,021.20 INR
2/18/20261,037.45 INR
2/17/20261,013.40 INR
2/16/20261,012.45 INR
2/13/20261,010.60 INR
2/12/20261,018.60 INR
2/11/20261,013.65 INR
2/10/2026966.35 INR
2/9/2026985.50 INR
2/6/2026950.55 INR
2/5/2026963.95 INR
2/4/2026980.30 INR
2/3/2026975.60 INR
2/2/2026953.95 INR
1/30/2026965.00 INR
1/29/2026973.30 INR
1/28/2026999.00 INR
1/27/20261,000.20 INR
1/23/20261,016.40 INR
1/22/20261,005.80 INR
1/21/2026987.90 INR
1/20/20261,035.50 INR
1/19/20261,062.70 INR
1/16/20261,076.80 INR
1/15/20261,090.50 INR
1/14/20261,090.50 INR
1/13/20261,058.30 INR
1/12/20261,043.20 INR
1/9/20261,083.00 INR
1/8/20261,100.90 INR
1/7/20261,128.50 INR
1/6/20261,115.90 INR
1/5/20261,103.20 INR
1/2/20261,106.50 INR
1/1/20261,110.40 INR
12/31/20251,108.00 INR
12/30/20251,091.90 INR
12/29/20251,081.40 INR
12/26/20251,085.00 INR
12/24/20251,084.80 INR
12/23/20251,068.40 INR
12/22/20251,064.20 INR
12/19/20251,045.20 INR
12/18/20251,015.50 INR
12/17/20251,010.00 INR
12/16/20251,001.30 INR
12/15/20251,004.90 INR
12/12/20251,012.30 INR
12/11/20251,019.30 INR
12/10/20251,018.40 INR
12/9/20251,021.40 INR
12/8/20251,004.10 INR
12/5/20251,026.10 INR
12/4/20251,013.50 INR
12/3/20251,016.50 INR
12/2/20251,020.20 INR
12/1/20251,029.40 INR
11/28/20251,031.35 INR
11/27/20251,003.20 INR
11/26/2025986.60 INR
11/25/2025977.55 INR
11/24/2025979.55 INR
11/21/2025978.20 INR
11/20/2025987.10 INR
11/19/2025987.50 INR
11/18/20251,006.90 INR
11/17/20251,021.85 INR
11/14/2025999.00 INR
11/13/2025997.05 INR
11/12/2025989.25 INR
11/11/2025985.70 INR
11/10/20251,001.05 INR
11/7/2025982.15 INR
11/6/2025979.80 INR
11/4/2025983.15 INR
11/3/2025975.40 INR
10/31/2025953.65 INR
10/30/2025970.35 INR
10/29/2025961.70 INR
10/28/2025959.65 INR
10/27/2025940.15 INR
10/24/2025926.40 INR
10/23/2025934.40 INR
10/21/2025923.90 INR
10/20/2025920.65 INR
10/17/2025900.05 INR
10/16/2025872.85 INR
10/15/2025875.30 INR
10/14/2025877.95 INR
10/13/2025874.30 INR
10/10/2025876.75 INR
10/9/2025865.10 INR
10/8/2025853.85 INR
10/7/2025863.40 INR
10/6/2025863.00 INR
10/3/2025864.40 INR
10/1/2025872.00 INR
9/30/2025841.80 INR
9/29/2025840.95 INR
9/26/2025832.30 INR
9/25/2025896.35 INR
9/24/2025909.75 INR
9/23/2025910.05 INR
9/22/2025903.80 INR
9/19/2025932.10 INR
9/18/2025923.25 INR
9/17/2025893.95 INR
9/16/2025894.85 INR
9/15/2025895.00 INR
9/12/2025896.05 INR
9/11/2025895.60 INR
9/10/2025896.40 INR
9/9/2025902.30 INR
9/8/2025895.20 INR
9/5/2025880.65 INR
9/4/2025874.10 INR
9/3/2025874.70 INR
9/2/2025860.10 INR
9/1/2025860.00 INR
8/29/2025856.90 INR
8/28/2025862.00 INR
8/26/2025868.65 INR
8/25/2025873.20 INR
8/22/2025879.10 INR
8/21/2025889.90 INR
8/20/2025876.05 INR
8/19/2025883.90 INR
8/18/2025865.65 INR
8/14/2025859.70 INR
8/13/2025863.15 INR
8/12/2025830.95 INR
8/11/2025831.50 INR
8/8/2025821.85 INR
8/7/2025838.25 INR
8/6/2025836.20 INR
8/5/2025857.50 INR
8/4/2025861.20 INR
Access this data via the Eulerpool API
Get Free API Key

Laurus Labs Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
49.36 B INR
11.75 B INR
8.28 B INR
Jan 1, 2023
60.41 B INR
12.94 B INR
7.90 B INR
Jan 1, 2024
50.41 B INR
3.95 B INR
1.61 B INR
Jan 1, 2025
55.54 B INR
6.25 B INR
3.58 B INR
Jan 1, 2026 (e)
68.85 B INR
11.59 B INR
8.74 B INR
Jan 1, 2027 (e)
79.85 B INR
13.45 B INR
11.50 B INR
Jan 1, 2028 (e)
92.79 B INR
15.62 B INR
14.01 B INR
Jan 1, 2029 (e)
107.02 B INR
18.02 B INR
17.65 B INR

Laurus Labs Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 3, 2026, 12:21 PM
 
REVENUEB INR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB INR
EBITB INR
EBIT MARGIN%
NET INCOMEB INR
NET INCOME GROWTH%
DIV.INR
DIV. GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
11.6013.2718.1119.3220.6922.9228.3248.1449.3660.4150.4155.5468.8579.8592.79107.02
–14.3936.516.657.1210.7723.5569.992.5322.39-16.5510.1823.9715.9816.2015.34
30.7128.2738.2444.9042.2846.0944.1751.0750.3047.6143.7148.4548.4548.4548.4548.45
3.563.756.938.678.7510.5612.5124.5824.8328.7622.0426.9133.3638.6944.9651.86
1.761.392.793.052.931.923.8313.5011.7512.943.956.2511.5913.4515.6218.02
15.2010.4815.3915.7914.188.3713.5228.0523.8021.427.8311.2616.8416.8416.8416.84
0.970.681.341.901.680.942.559.848.287.901.613.588.7411.5014.0117.65
–-29.6395.4742.33-11.93-44.03172.17285.23-15.86-4.52-79.69123.24143.9631.5321.8525.98
–––1.501.501.503.301.873.201.600.801.601.601.922.30–
––––––120.00-43.3371.12-50.00-50.00100.00–20.0019.79–
529.00529.00529.00455.00532.00533.00533.00538.12539.17539.60539.67539.59539.59539.59539.59539.59
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Laurus Labs generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Laurus Labs retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Laurus Labs's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Laurus Labs has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Laurus Labs's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Laurus Labs stock margins

The Laurus Labs margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Laurus Labs. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Laurus Labs.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
51.07 %
28.05 %
20.43 %
Jan 1, 2022
50.30 %
23.80 %
16.77 %
Jan 1, 2023
47.61 %
21.42 %
13.08 %
Jan 1, 2024
43.71 %
7.83 %
3.18 %
Jan 1, 2025
48.45 %
11.26 %
6.45 %
Jan 1, 2026 (e)
48.45 %
16.84 %
12.70 %
Jan 1, 2027 (e)
48.45 %
16.84 %
14.40 %
Jan 1, 2028 (e)
48.45 %
16.84 %
15.10 %

Laurus Labs Stock Revenue, EBIT, Earnings per Share

The Laurus Labs earnings per share therefore indicates how much revenue Laurus Labs has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
89.45 INR
25.09 INR
18.28 INR
Jan 1, 2022
91.54 INR
21.78 INR
15.35 INR
Jan 1, 2023
111.94 INR
23.97 INR
14.64 INR
Jan 1, 2024
93.41 INR
7.32 INR
2.97 INR
Jan 1, 2025
102.93 INR
11.59 INR
6.64 INR
Jan 1, 2026 (e)
127.54 INR
21.48 INR
16.19 INR
Jan 1, 2027 (e)
147.91 INR
24.92 INR
21.30 INR
Jan 1, 2028 (e)
171.87 INR
28.95 INR
25.95 INR

Laurus Labs business model & stock analysis

Laurus Labs Ltd is an Indian pharmaceutical company specializing in the production of active pharmaceutical ingredients for generics and innovative drugs. Since its establishment in 2005, the company has become one of the leading providers of API products on the global market. Answer: Laurus Labs Ltd is an Indian pharmaceutical company specializing in the production of active pharmaceutical ingredients for generics and innovative drugs.

Laurus Labs SWOT Analysis

Strengths

Laurus Labs Ltd possesses several key strengths that contribute to its success and competitive advantage. These include:

  • Strong portfolio of high-quality and affordable generic pharmaceutical products.
  • Advanced manufacturing facilities and processes, ensuring efficiency and quality control.
  • Extensive research and development capabilities, driving innovation and new product development.
  • Established partnerships and collaborations with global pharmaceutical companies.
  • Solid financial performance and steady revenue growth.

Weaknesses

Despite its strengths, Laurus Labs Ltd also faces certain weaknesses that may hinder its growth and competitiveness. These include:

  • Reliance on a limited number of key customers, which increases dependency risks.
  • Limited geographical diversification, with a significant portion of revenue coming from a few markets.
  • Potential vulnerability to changing regulatory environments and policies in various countries.
  • Relative lack of brand recognition and differentiation in a highly competitive industry.
  • Limited product pipeline diversification, exposing the company to market and product-specific risks.

Opportunities

Laurus Labs Ltd can leverage various opportunities to enhance its market position and drive growth. These opportunities include:

  • Increasing global demand for affordable generic pharmaceuticals.
  • Expanding into new markets and geographies to reduce dependency on specific regions.
  • Growing emphasis on research and development in the pharmaceutical industry, opening avenues for partnerships and collaborations.
  • Growing preference for outsourcing manufacturing and development activities by global pharmaceutical companies.
  • Potential entry into high-growth therapeutic segments through strategic acquisitions or licensing agreements.

Threats

Laurus Labs Ltd faces certain threats that could impact its business performance and market position, including:

  • Intense competition from other generic pharmaceutical manufacturers, which may lead to pricing pressures.
  • Stringent regulatory requirements and compliance standards in the pharmaceutical industry.
  • Risks associated with intellectual property rights and patent infringement lawsuits.
  • Fluctuating raw material prices and supply chain disruptions.
  • Economic and political uncertainties in key markets, affecting demand and business operations.

Laurus Labs Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Laurus Labs historical P/E ratio, EBIT multiple, and P/S ratio

Laurus Labs annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Laurus Labs shares outstanding

The number of shares of Laurus Labs was 539.59 M in 2025. This indicates how many shares Laurus Labs is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
538.12 M Stocks
Jan 1, 2022
539.17 M Stocks
Jan 1, 2023
539.60 M Stocks
Jan 1, 2024
539.67 M Stocks
Jan 1, 2025
539.59 M Stocks
Jan 1, 2026 (e)
539.59 M Stocks
Jan 1, 2027 (e)
539.59 M Stocks
Jan 1, 2028 (e)
539.59 M Stocks

Laurus Labs stock splits

In Laurus Labs's history, there have been no stock splits.

Laurus Labs Dividend History

9 years of dividend payments

YearAnnual DividendYoY ChangePayments
20251.60INR↑ 100.0%2×
May 9, 20250.80INR↑ 100.0%1/2
Oct 31, 20250.80INR 0.0%2/2
20240.80INR↓ 50.0%2×
20231.60INR↓ 20.0%2×
20222.00INR 0.0%2×
20212.00INR↓ 39.4%3×
20203.30INR↑ 120.0%3×
20191.50INR 0.0%1×
20181.50INR 0.0%1×
20171.50INR—1×

Laurus Labs dividend history and estimates

In 2025, Laurus Labs paid a dividend amounting to 1.60 INR. Dividend means that Laurus Labs distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021 (e)
2.00 INR
-0.13 INR
Jan 1, 2022 (e)
2.00 INR
1.20 INR
Jan 1, 2023
1.60 INR
0.00 INR
Jan 1, 2024
0.80 INR
0.00 INR
Jan 1, 2025
1.60 INR
0.00 INR
Jan 1, 2026
1.60 INR
0.00 INR
Jan 1, 2027 (e)
0.00 INR
1.92 INR
Jan 1, 2028 (e)
0.00 INR
2.30 INR

Laurus Labs dividend payout ratio

In 2025, Laurus Labs had a payout ratio of 24.09%. The payout ratio indicates the percentage of the company's profits that Laurus Labs distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
10.94 %
Jan 1, 2022
13.03 %
Jan 1, 2023
10.93 %
Jan 1, 2024
26.89 %
Jan 1, 2025
24.09 %
Jan 1, 2026 (e)
9.88 %
Jan 1, 2027 (e)
9.01 %
Jan 1, 2028 (e)
8.88 %

Current Laurus Labs forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
15.56 %
Buy
25.00 % (5)
Hold
25.00 % (5)
Sell
50.00 % (10)
12M Price Target
1,060.80
Last Price
1,816.20
Currency
INR
12M Return Potential
-41.59 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the Laurus Labs stock

51/100
55
Environment
74
Social
24
Governance
E

Environment

20
Scope 1 - Direct Emissions198,782
Scope 2 - Indirect emissions from purchased energy176,678
Scope 3 - Indirect emissions within the value chain87,212
Total CO₂ emissions375,460
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees7
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Laurus Labs shareholder structure

% Name
11.20405%
Capital Research Global Investors
Capital Research Global Investors
2.17083%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
2.02937%
Mirae Asset Global Investments (India) Pvt. Ltd.
Mirae Asset Global Investments (India) Pvt. Ltd.
1.44633%
SBI Funds Management Pvt. Ltd.
SBI Funds Management Pvt. Ltd.
1.19089%
Goldman Sachs Asset Management International
Goldman Sachs Asset Management International
0.95004%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.

Laurus Labs Beneficial Ownership Filings (SEC 13D/G)

Free Float
92.3%
Float Shares
-
Shares Outstanding
-

Laurus Labs Executives and Management Board

28 members · avg. age 55 · 7 % women

SC

Dr. Satyanarayana Chava (64)

Chief Executive Officer, Executive Director · since 2015

131.47 M INR

Management

VV

Mr. Venkata Ravi Vantaram (60)

Chief Financial Officer, Executive Director · since 2015

45.26 M INR
GR

Mr. Gogireddy Reddy

Compliance Officer, Company Secretary · since 2022

6.40 M INR
VR

Dr. V. Uma Maheswer Rao

President Chemical R and D · since 2023

–
SS

Mr. Srinivasa Suryadevara (57)

President - Manufacturing and Operations · since 2023

–
TV

Mr. Thomas Versosky

President - FDF, North America

–
JA

Mr. Jyothi Basu Abbibeni

Executive Vice President - Chemical R and D

–

Board of Directors

CR

Dr. Chunduru Venkata Rao (63)

Executive Director - Quality

29.53 M INR
KC

Mr. Krishna Chava (35)

Executive Director - Synthesis

18.43 M INR
SC

Ms. Soumya Chava (38)

Executive Director - Generics · since 2024

11.19 M INR
RC

Dr. Rajesh Chandy (55)

Non-Executive Independent Director

4.39 M INR
AB

Ms. Aruna Bhinge

Non-Executive Independent Director

3.00 M INR
RK

Dr. Ravindranath Kancherla (70)

Non-Executive Independent Chairman of the Board

2.60 M INR

Frequently asked questions about Laurus Labs

Laurus Labs Ltd is primarily present in various countries and regions across the globe. The company has established a significant presence in India, where its headquarters are located. In addition, Laurus Labs Ltd has a strong presence in the United States, Europe, and other key markets. With its comprehensive global reach, the company is able to cater to a diverse customer base and leverage its international operations for growth and market expansion.

The business model of Laurus Labs Ltd is centered around the development, manufacturing, and marketing of generic active pharmaceutical ingredients (APIs) and formulations. Laurus Labs specializes in offering cost-effective and high-quality healthcare solutions, serving both domestic and international markets. The company operates across various segments such as APIs, generic formulations, synthesis and nutraceuticals. Laurus Labs focuses on innovation, research and development, and maintaining strong customer relationships to drive growth and expansion in the pharmaceutical industry. With its expertise in the production of APIs and formulations, Laurus Labs aims to provide affordable healthcare solutions, contributing to the betterment of global health.

Laurus Labs Ltd is primarily active in the pharmaceutical industry.

The main competitors of Laurus Labs Ltd in the market include generic pharmaceutical companies such as Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Cipla Limited, Lupin Limited, and Aurobindo Pharma. These companies also specialize in the production and distribution of generic drugs, actively competing with Laurus Labs in terms of product offerings, pricing, and market share.

Laurus Labs Ltd, founded in 2005, is a leading research-driven pharmaceutical company based in Hyderabad, India. With a focus on developing and manufacturing high-quality generic Active Pharmaceutical Ingredients (APIs) and finished dosage forms, Laurus Labs has emerged as a global leader in the healthcare industry. The company's strong commitment to innovation, quality, and sustainability has facilitated its growth into a diversified and vertically integrated organization. Laurus Labs caters to diverse therapeutic areas such as antiretrovirals (ARVs), oncology, hepatitis C, and other chronic diseases. Through strategic partnerships, state-of-the-art infrastructure, and a diligent team, Laurus Labs continues to deliver transformative healthcare solutions worldwide.

Laurus Labs Ltd, a leading pharmaceutical company, has achieved significant milestones over the years. One notable achievement is its successful listing on the stock exchanges in 2016, marking a significant step in its growth trajectory. The company's robust expansion plans and strategic acquisitions have further strengthened its position in the industry. Laurus Labs Ltd has also received several prestigious certifications, including the USFDA approval for its manufacturing facilities, showcasing its commitment to quality and compliance. The company's consistent revenue growth and strong financial performance have earned it recognition as one of the fastest-growing pharmaceutical companies in India.

Laurus Labs Ltd represents strong values and a robust corporate philosophy. The company focuses on delivering high-quality generic active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). Laurus Labs promotes integrity, innovation, and sustainability throughout its operations. With a customer-centric approach, the company strives to provide affordable healthcare solutions globally. Laurus Labs aims to enhance access to affordable medicines while adhering to stringent quality standards. Through continuous research and development, Laurus Labs aims to develop innovative products that cater to the evolving needs of the pharmaceutical industry. The company's commitment to excellence and continuous improvement defines its corporate philosophy.

Analysts currently set an average price target of 1,014.43 INR for the Laurus Labs stock (median: 1,060.80 INR), implying -44.1 % versus the latest price. The consensus is based on 20 analyst ratings.

Laurus Labs Analyst Price Targets 2026

20 analysts currently rate the Laurus Labs stock: 5 recommend buying, 5 holding and 10 selling. For 2026, analysts expect Laurus Labs to generate revenue of 68.85 B INR and earnings per share of 16.20 INR.

Laurus Labs Analyst Price Targets 2026

Converted at the current exchange rate, the Laurus Labs share trades at 16.54 EUR (1,816.20 INR).

Laurus Labs Ltd is a leading pharmaceutical company that delivers innovative solutions for the healthcare industry. The company has been operating in Hyderabad, India since 2005 and currently employs over 6,500 employees. The business model of Laurus Labs consists of three main divisions: generics, active pharmaceutical ingredients (API), and synthesis. The generics division focuses on manufacturing high-quality and affordable generics that are marketed worldwide. The API division produces pharmaceutical raw materials used by global pharmaceutical companies to manufacture their own products. The synthesis division produces intermediate products and specialty chemicals used in various industries such as cosmetics, agrochemicals, and polymer processing industries. Laurus Labs' products include a wide range of generics in various therapy areas such as oncology, HIV, hepatitis C, CNS, and cardiovascular. Some of the company's key medications include Abacavir, Emtricitabine, Dolutegravir, Lopinavir, Ritonavir, and Pregabalin. The company also manufactures over 50 API products including Duloxetine, Rivaroxaban, Apixaban, and Varenicline Tartrate. Laurus Labs has a strong research and development department with 400+ scientists focusing on the research of generics and innovative drugs. The company also has partnerships with several high-profile global pharmaceutical companies such as Pfizer, Aspen, Teva, and Merck. Laurus Labs has a business model focused on quality, agility, and customer orientation. The company has state-of-the-art production facilities validated according to international standards such as FDA, EU-GMP, and TGA. The company has one of the largest capacities for scaling up API products in India. The company also has a professional sales team with a strong presence in North America, Europe, and Asia. The company is also committed to achieving its sustainability goals and minimizing the environmental impact of its activities. The company has taken measures to improve energy efficiency, waste reduction, and wastewater treatment. In summary, Laurus Labs' business model is focused on a highly diversified production of generics, API, and synthesis products. The company has earned an excellent reputation for quality, agility, and customer orientation and has strong partnerships with global pharmaceutical companies. With a strong research and development department, Laurus Labs aims to continue growing in the pharmaceutical industry and delivering innovative solutions for the healthcare industry.

The expected revenue of Laurus Labs is 68.85 B INR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Laurus Labs is 8.74 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Laurus Labs is currently 112.11. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Laurus Labs stock.

The price-to-sales ratio (P/S) of Laurus Labs is currently 14.23. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Laurus Labs stock.

The Eulerpool Quality Score for Laurus Labs is 4/10.

The ISIN of Laurus Labs is INE947Q01028. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Laurus Labs is LAURUSLABS.NS. The ticker symbol is used to trade Laurus Labs shares on the stock exchange.

Over the past 12 months, Laurus Labs paid a dividend of 1.60 INR . This corresponds to a dividend yield of about 0.09 %. For the coming 12 months, Laurus Labs is expected to pay a dividend of 1.92 INR.

The current dividend yield of Laurus Labs is 0.09 %.

Laurus Labs pays a dividend, distributed in the months of , , , .

Laurus Labs paid dividends every year for the past 9 years.

For the upcoming 12 months, dividends amounting to 1.92 INR are expected. This corresponds to a dividend yield of 0.11 %.

Laurus Labs is assigned to the 'Health' sector.

To receive the latest dividend of Laurus Labs from amounting to 0.8 INR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Laurus Labs distributed 1.6 INR as dividends.

The dividends of Laurus Labs are distributed in INR.

All fundamentals and in-depth analysis of Laurus Labs

Our stock analysis for Laurus Labs stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Laurus Labs. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Laurus Labs Stock
Laurus Labs Revenue→
Laurus Labs Stock
Laurus Labs Net Income→
Laurus Labs Stock
Laurus Labs P/E→
Laurus Labs Stock
Laurus Labs P/S→
Laurus Labs Stock
Laurus Labs EBIT→
Laurus Labs Stock
Laurus Labs Dividend→
Laurus Labs Stock
Laurus Labs Directors Dealings→
Laurus Labs Stock
Laurus Labs Stocks→
Laurus Labs Stock
Laurus Labs Market capitalization→
Laurus Labs Stock
Laurus Labs Debt→
Laurus Labs Stock
Laurus Labs Liabilities→
Laurus Labs Stock
Laurus Labs Equity→
Laurus Labs Stock
Laurus Labs AAQS→
Laurus Labs Stock
Laurus Labs Employees→
Laurus Labs Stock
Laurus Labs ROE→
Laurus Labs Stock
Laurus Labs ROA→
Laurus Labs Stock
Laurus Labs ROCE→
Laurus Labs Stock
Laurus Labs News→
Laurus Labs Stock
Laurus Labs Analyst Price Targets→

Health Stocks

LavipharmLaserOptek CoLB PharmaceuticalsLasa SupergenericsLDC Dental PCLLarkbergetLegend BiotechLarimar TherapeuticsLeMaitre VascularLanzhou Foci Pharmaceutical CoLENSARLantheus HoldingsAll Stocks A–Z →